S. Siddiqui (Leicester, United Kingdom), C. Pelaia (Catanzaro (CZ), Italy)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Utility of Interleukin-5 in phenotyping allergic versus non allergic asthma
D. Bajaj (Lucknow (Uttar Pradesh), India), N. Kumar (Lucknow (Uttar Pradesh), India), R. Tyagi (Lucknow (Uttar Pradesh), India), J. Bajpai (Lucknow (Uttar Pradesh), India), S. Kant (Lucknow (Uttar Pradesh), India), R. Kushwaha (Lucknow (Uttar Pradesh), India), A. Verma (Lucknow (Uttar Pradesh), India)
|   |
Characteristics of a real world cohort of Canadians treated with benralizumab
S. Noorduyn (Mississauga, Canada), M. Hamilton (Toronto, Canada), B. Lancaster (Mississauga, Canada), A. Gendron (Montreal, Canada), L. Mbuagbaw (Hamilton, Canada), E. Penz (Saskatoon, Canada)
| |
Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study
S. da Costa Martins (Covilhã, Portugal), E. Tinoco (Vila Nova de Gaia, Portugal), B. Cabrita (Matosinhos, Portugal), D. Machado (Vila Nova de Gaia, Portugal), I. Franco (Vila Nova de Gaia, Portugal), I. Ladeira (Vila Nova de Gaia, Portugal), I. Pascoal (Vila Nova de Gaia, Portugal), R. Lima (Vila Nova de Gaia, Portugal), S. Valente (Covilhã, Portugal)
| |
Spanish consensus on the characteristics of severe asthmatic patients under biological treatment suitable for at home administration
A. Gomez-Bastero Fernandez (Sevilla, Spain), E. Chiner (Alicante, Spain), C. Cisneros Serrano (Madrid, Spain), J. Igea (Salamanca, Spain), E. Villamañán Bueno (Madrid, Spain), M. Rial (A Coruña, Spain), M. Pla Martí (Valencia, Spain), V. López Carrasco (Madrid, Spain), A. Martínez Meca (Madrid, Spain), L. Fernández Lisón (Cáceres, Spain), M. Sánchez-Herrero (Madrid, Spain), B. Velasco-Laorga (Madrid, Spain)
| |
Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE)
F. Kanniess (Reinfeld (Holstein), Germany), L. Tamasi (Budapest, Hungary), R. R. Mroz (Bialystok, Poland), P. Bakakos (Athens, Greece), S. Tubis (Wedel, Germany), G. Resler Plat (Madrid, Spain), A. Shavit (Wedel, Germany)
| |
Heterogeneous response of airway eosinophilia to biologics in severe asthma patients
S. Škrgat (Ljubljana, Slovenia), M. Kopac (Ljubljana, Slovenia), M. Rijavec (Golnik, Slovenia), U. Bidovec Stojkovic (Golnik, Slovenia), I. Kern (Golnik, Slovenia), R. Vantur (Golnik, Slovenia), P. Korošec (Golnik, Slovenia)
| |
Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma.
M. Humbert (Le Kremlin-Bicêtre, France), A. Bourdin (Montpellier, France), A. Deschildre (Lille, France), M. Molimard (Bordeaux, France), C. Taille (Paris, France), D. Kamar (Rueil Malmais, France), C. Thonnelier (Rueil Malmaison, France), A. Lajoinie (Lyon, France), A. Rigault (Lyon, France)
| |
Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment.
A. Bjerrum (Århus, Denmark), S. Tina (Århus, Denmark), S. Johannes Martin (Århus, Denmark)
| |
Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
L. Sher (Rolling Hills Estates, CA, United States of America), G. Passalacqua (Genoa, Italy), C. Taillé (Paris, France), L. Cohn (New Haven, CT, United States of America), S. Quirce (Madrid, Spain), N. Daizadeh (Cambridge, MA, United States of America), N. Pandit-Abid (Bridgewater, NJ, United States of America), B. Ortiz (Tarrytown, NY, United States of America), A. Khan (Chilly-Mazarin, France), Y. Zhang (Tarrytown, NY, United States of America)
| |
Identifying super-responders to benralizumab in severe asthma
D. Jackson (London, United Kingdom), T. Harrison (Nottingham; Cambridge, United Kingdom), F. Menzella (Reggio Emilia, Italy), V. Shih (Gaithersburg, United States of America), A. Burden (Cambridge, United Kingdom), E. Garcia Gil (Barcelona, Spain)
| |
Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
F. Menzella (Reggio Emilia, Italy), M. Aliani (Bari, Italy), E. Altieri (Garbagnate Milanese (MI), Italy), P. Bracciale (Ostuni (BR), Italy), S. Centanni (Milano, Italy), F. De Michele (Napoli, Italy), F. Di Marco (Bergamo, Italy), G. Pelaia (Catanzaro, Italy), M. Romagnoli (Treviso, Italy), P. Schino (Bari, Italy), S. Boarino (Basiglio (MI), Italy), G. Vitiello (Basiglio (MI), Italy), P. Rogliani (Roma, Italy)
| |
Eosinophils in bronchial biopsy predict functional response to biological therapy in severe asthma
H. Shafiek (Alexandria, Egypt), A. Iglesias (Palma de Mallorca, Spain), C. Gomez (Palma de Mallorca, Spain), M. Mosteiro (Vigo, Spain), J. Ramos (Salamanca, Spain), A. Viña (Madrid, Spain), L. Perez De Llano (Lugo, Spain), . Torrego (Barcelona, Spain), I. Escribano (Madrid, Spain), C. Almonacid (Madrid, Spain), C. Melero (Madrid, Spain), C. Pinedo (Madrid, Spain), B. Cosio (Palma de Mallorca, Spain)
| |
Severe asthma outcomes over two years of therapy with mepolizumab
L. Elsey (Manchester, United Kingdom), T. Pantin (Manchester, United Kingdom), L. Holmes (Manchester, United Kingdom), G. Tavernier (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom)
| |
Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study
S. Pereira (Lille, France), N. Bautin (France), J. Verhille (Lille, France), P. Bonniaud (Dijon, France), G. Devouassoux (Lyon, France), S. Fry (Lille, France), L. Guilleminault (Toulouse, France), N. Khayath (Strasbourg, France), C. Leroyer (Brest, France), C. Chenivesse (Lille, France), N. Bautin (Lille, France)
| |
Impact of biologic therapy in severe asthma with nasal polyps
E. M. Tinoco (Vila Nova de Gaia , Portugal), A. Gigante (Vila Nova de Gaia , Portugal), A. Fernandes (Matosinhos, Portugal), B. Cabrita (Matosinhos, Portugal), C. Santa (Vila Nova de Gaia , Portugal), I. Sucena (Vila Nova de Gaia , Portugal), M. Silva (Vila Nova de Gaia , Portugal), S. Martins (Covilhã, Portugal), D. Machado (Vila Nova de Gaia , Portugal), I. Franco (Vila Nova de Gaia , Portugal), I. Ladeira (Vila Nova de Gaia , Portugal), I. Pascoal (Vila Nova de Gaia , Portugal), R. Lima (Vila Nova de Gaia , Portugal)
| |
Real-world Omalizumab and Mepolizumab treated Difficult Asthma Phenotypes and their Clinical Outcomes
W. Fong (Southampton, United Kingdom), A. Azim (Southampton, United Kingdom), D. Knight (Southampton, United Kingdom), H. Mistry (Southampton, United Kingdom), A. Freeman (Southampton, United Kingdom), M. Felongco (Southampton, United Kingdom), A. Kyyaly (Southampton, United Kingdom), M. Harvey (Southampton, United Kingdom), P. Dennison (Southampton, United Kingdom), H. Zhang (Memphis, United States of America), P. Howarth (Southampton, United Kingdom), S. Arshad (Southampton, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom)
| |
Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
M. Oliver (Oxford, United Kingdom), S. Poole (Oxford, United Kingdom), C. Borg (Oxford, United Kingdom), C. Connolly (Oxford, United Kingdom), I. Pavord (Oxford, United Kingdom), T. Hinks (Oxford, United Kingdom), S. Couillard (Oxford, United Kingdom)
| |
The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma
S. Hansen (Copenhagen, Denmark), C. Ulrik (Hvidovre, Denmark), O. Hilberg (Vejle, Denmark), A. Von Bülow (Copenhagen, Denmark), A. Christiansen (Odense, Denmark), C. Johnsen (Gentofte, Denmark), J. Schmid (Aarhus, Denmark), A. Bjerrum (Aarhus, Denmark), K. Assing (Aalborg, Denmark), A. Wimmer-Aune (Aalborg, Denmark), N. Krogh (Copenhagen, Denmark), L. Rasmussen (Gentofte, Denmark), C. Porsbjerg (Copenhagen, Denmark)
| |
Real-World Experience with dupilumab in Severe Asthma: One year data from an Italian Named Patient Program
S. Nolasco (Catania, Italy), R. Campisi (Catania, Italy), C. Crimi (Catania, Italy), N. Scichilone (Palermo, Italy), M. Porto (Catania, Italy), G. Guarnieri (Padova, Italy), A. Papi (Ferrara, Italy), B. Beghé (Modena, Italy), P. Impellizzeri (Catania, Italy), N. Crimi (Catania, Italy)
| |